CoreRx, Societal CDMO, and Bend Bioscience Unite Under the Bend Bioscience Brand to Provide World Class CDMO offering

BEND, Ore., Sept. 4, 2024 /PRNewswire/ -- In a significant move, CoreRx, Societal CDMO, and Bend Bioscience have announced their unification under the Bend Bioscience brand. This merger brings together three highly respected organizations, each with a unique legacy and distinct strengths, to form a comprehensive contract development and manufacturing organization (CDMO) that offers an end-to-end suite of services.


The decision to adopt the Bend Bioscience name reflects the company's commitment to innovation, technical excellence and unmatched customer service; a reputation established by Bend Bioscience since its inception. However, this unification equally honors the rich legacies of CoreRx and Societal CDMO, whose contributions and expertise will be foundational to the new brand.


CoreRx has long been recognized for its innovation in formulation development, providing customized, cutting-edge solutions that address some of the most complex challenges in drug development. Their specialized knowledge in the creation of innovative drug delivery systems and complex formulations will continue to be a critical component of Bend Bioscience's expanded service offerings.


Societal CDMO provides deep expertise in scalable manufacturing and commercial production, with a proven track record of quality and reliability. Their robust capabilities in cGMP manufacturing, packaging, and supply chain management complement the scientific and technical strengths of both CoreRx and Bend Bioscience, allowing the newly combined organization to offer a fully integrated development-to-commercialization pathway for its clients.


KEEP READING: https://www.prnewswire.com/news-releases/corerx-societal-cdmo-and-bend-bioscience-unite-under-the-bend-bioscience-brand-to-provide-world-class-cdmo-offering-302237436.html

Website: https://bendbioscience.com/

Georgia Life Science's Feature in Very First Atlanta Edition of Inside Medicine

March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.

UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem

March 24, 2026
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta

Georgia General Assembly Establishes Life Sciences Caucus to Advance Innovation and Industry Growth

March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
MORE POSTS